Types of Cancer We Treat

Prostate Cancer

Our nationally and internationally known specialists offer the most up-to-date, research-backed prostate cancer treatments, including targeted ablation using cryo-ablation and high-intensity focused ultrasound, or HIFU. Our comprehensive services include precision screening, diagnosis, post-treatment rehabilitation, and integrative therapies, as well as second opinion consultations to help you better understand your testing and treatment options.

Perlmutter Cancer Center doctors share in the growing consensus among top prostate cancer specialists that many men are being overtreated for prostate cancer. We work together to identify which men are best served by aggressive treatment and those who can be treated safely with a more conservative approach. We believe in empowering you with information, so that you can actively partner in creating a personalized treatment plan that’s right for you.

Find a Doctor & Schedule
Diagnosis
Active Surveillance
Surgery
Radiation Therapy
Minimally Invasive Ablation Treatment
Hormone Therapies & Other Systemic Therapies

Related News

Progress & Need for Improvement in Treating Prostate Cancer
Read Story
Study of Long-Term Hormone Therapy for Prostate Cancer
Read Story
New Treatments Help Manage Metastatic Prostate Cancer
Read Story
How Gene Testing Helps Predict Success with Immunotherapy
Read Story
MRI is Cost-Effective for Prostate Cancer Surveillance
Read Story
Study Examines Racial Disparities in Prostate Cancer Care
Read Story
Initiative Seeks to Stamp Out Cancer in Brooklyn
Read Story
Popular YouTube Videos Mislead on Bladder & Prostate Cancer
Read Story
High-Tech Radiation Treatment Shortens Recovery Time
Read Story
New Study Tests MRI-Targeted Prostate Biopsy Strategy
Read Story
Biomarker Tests Yield Conflicting Advice on Prostate Biopsy
Read Story
Study Examines Early Biopsy After Partial-Gland Cryoablation
Read Story

Clinical Trials and Research Studies

Phase 3

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk clinically localised prostate cancer

Learn More

Phase 5

A Phase 1 and 2a trial of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer

Learn More

Phase 5

10301 - A Phase I and Randomized Phase II Trial of Radium-223 dichloride M3814 & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Learn More

Phase 3

PSMAfore: A phase III Open-label Multi-Center Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Na ve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

Learn More
View All Related Clinical Trials (9)